Australia Leukocyte Adhesion Deficiency (LAD-I) Market Report 2023 to 2030

Australia Leukocyte Adhesion Deficiency (LAD-I) Market Analysis

$ 3999

Australia Leukocyte Adhesion Deficiency (LAD-I) therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. An uncommon genetic condition called leukocyte adhesion deficiency (LAD-I) impairs the immune system's capacity to combat infections. There is currently no cure for LAD-I, and there are few effective treatments available. To fill this unmet medical need, new medicines are becoming more and more popular. Vertex Pharmaceuticals, Orpha Labs, Avalo Therapeutics, Inc., Rocket Pharmaceuticals, Inc., Aspen Neuroscience, Magenta Therapeutics, Rubius Therapeutics, Enochian Biosciences, Sana Biotechnology, and Sigma-Aldrich are major global players.

ID: IN10AURD096 CATEGORY: Rare Diseases GEOGRAPHY: Australia AUTHOR: Sakshi Mantri

Buy Now

Australia Leukocyte Adhesion Deficiency (LAD-I) Market Analysis Summary

Australia Leukocyte Adhesion Deficiency (LAD-I) Market is valued at around $0.09 Mn in 2022 and is projected to reach $0.17 Mn by 2030, exhibiting a CAGR of 7.7% during the forecast period 2023-2030.

An uncommon autosomal recessive paediatric condition called Leukocyte Adhesion Deficiency-I (LAD-I) is brought on by mutations in the ITGB2 gene, which codes for the protein CD18, a component of beta-2 integrins. Leukocyte adhesion and extravasation from blood arteries to fight infections are made possible by the crucial protein CD18. Children with severe LAD-I therefore frequently have symptoms soon after birth. They experience repeated, sometimes fatal bacterial and fungal infections during infancy, which necessitate many hospitalizations and poor treatment response. Recurrent severe infections in infants who survive infancy include pneumonia, gingival ulcers, necrotic skin ulcers, and septicemia. Patients with severe LAD-I have a death rate of 60–75 per cent before the age of 2, and survival past the age of five is unusual without a successful bone marrow transplant. Patients with severe LAD-I have a large unmet medical need.

There is currently no cure for LAD-I, and there are few effective treatments available. To fill this unmet medical need, new medicines are becoming more and more popular. There is optimism that novel medicines for LAD-I will be licensed soon given the rising interest in rare diseases and the expanding number of incentives provided by regulatory agencies.

Vertex Pharmaceuticals, Orpha Labs, Avalo Therapeutics, Inc., Rocket Pharmaceuticals, Inc., Aspen Neuroscience, Magenta Therapeutics, Rubius Therapeutics, Enochian Biosciences, Sana Biotechnology, and Sigma-Aldrich are major global players.

Market Dynamics

Market Drivers

There is currently no cure for LAD-I, and there are few effective treatments available. To fill this unmet medical need, new medicines are becoming more and more popular. Currently, a number of businesses are working to develop gene therapies and biologics as LAD-I treatments. However, there is hope that new treatments for LAD-I will be approved soon due to the rising interest in rare diseases and the growing number of incentives provided by regulatory agencies. Therefore, the LAD-I market offers a compelling prospect for businesses willing to make an investment in this field.

Market Development

For severe Leukocyte Adhesion Deficiency-I, Rocket's ex vivo lentiviral gene therapy candidate is called RP-L201 (LAD-I).
All nine LAD-I patients with 12 to 24 months of follow-up available had observed 100% overall survival through Kaplan Meier estimate at 12 months post-infusion. The data also showed improvement in wound healing skills and remission of a skin rash associated with LAD-I.
There have been no significant adverse events associated with RP-L201 to date, but all patients had a very positive safety profile for the drug. It has been previously reported that adverse effects connected to other study techniques, such as busulfan conditioning, are consistent with the safety profiles of those agents and techniques.
Rocket expects to submit the Biologics License Application (BLA) with the FDA in the second quarter of 2023 in light of the promising efficacy and safety data from the Phase 2 pivotal LAD-I study.

Restraints of Australia Leukocyte Adhesion Deficiency (LAD-I) Therapeutics Market

Because of the high cost of development and the small patient population, companies are likely to encounter difficulties while bringing their medications to market.

Key players

BioMarin Pharmaceutical Inc. Pfizer Sanofi Shire plc Catalyst Biosciences uniQure Ionis Pharmaceuticals Alnylam Pharmaceuticals Intercept Pharmaceuticals Novartis

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Australia Leukocyte Adhesion Deficiency (LAD-I) Therapeutics Market

By Treatment

Hematopoietic Stem Cell Transplantation
Recombinant Human Interferon-gamma Treatment
Prophylactic Immunoglobulin Therapy
Antimicrobial Therapy
Prophylactic Therapy
Fucose Supplementation
Monoclonal Antibodies
Coagulation Factors

By End Users

Hospitals
Specialty Clinics
Others

Insights10 will provide you with the reports within 10 key parameters which are:

Market Overview
Market Growth Drivers & Restraints
Epidemiology of Disease Type
Market Segmentation
Market Share
Competitive Landscape
Key Company Profiles
Healthcare Policies & Regulatory Framework
Reimbursement Scenario
Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

Establishing market drivers and trends
Analyzing the regulatory landscape to understand future growth
Market Segment based analysis to obtain revenue/volume
Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.